<rst>
<header>
	<relations>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">1. Introduction</segment>
<segment id="2" parent="1004" relname="span">Cutaneous squamous cell carcinoma</segment>
<segment id="3" parent="2" relname="elaboration">( cSCC )</segment>
<segment id="4" parent="1003" relname="same_unit">is the second most common type of cancer</segment>
<segment id="5" parent="1002" relname="same_unit">with an annual incidence of over one million globally .</segment>
<segment id="6" parent="1007" relname="span">Chronic ultraviolet</segment>
<segment id="7" parent="6" relname="elaboration">( UV )</segment>
<segment id="8" parent="1008" relname="span">exposure was suggested to be responsible for DNA damage of normal keratinocytes in the epidermis ,</segment>
<segment id="9" parent="8" relname="elaboration">which leads to the development of skin cancers including cSCC .</segment>
<segment id="10" parent="1010" relname="preparation">However , the detailed underlying molecular mechanisms for this transition still need to be fully elucidated .</segment>
<segment id="11" parent="1011" relname="span">Apoptosis is one type of programmed cell death ,</segment>
<segment id="12" parent="1012" relname="joint">which is initiated by intrinsic or extrinsic signals</segment>
<segment id="13" parent="1013" relname="span">and finely-tuned by many factors</segment>
<segment id="14" parent="13" relname="elaboration">including BCL-2 family proteins .</segment>
<segment id="15" parent="1016" relname="span">BCL-2 family members , including both anti-apoptotic and pro-apoptotic BCL-2 family proteins , govern mitochondrial outer membrane permeabilization</segment>
<segment id="16" parent="15" relname="restatement">( MOMP )</segment>
<segment id="17" parent="1016" relname="purpose">to regulate apoptosis .</segment>
<segment id="18" parent="1019" relname="circumstance">When apoptotic cell death program starts ,</segment>
<segment id="19" parent="1019" relname="joint">MOMP releases cytochrome c to cytosol</segment>
<segment id="20" parent="1020" relname="span">and activates caspase-family proteases</segment>
<segment id="21" parent="20" relname="purpose">for initiating apoptotic events .</segment>
<segment id="22" parent="1023" relname="span">Tumors develop effective mechanisms</segment>
<segment id="23" parent="22" relname="purpose">to resist apoptosis</segment>
<segment id="24" parent="1010" relname="joint">and thus become one of the hallmark features of cancer .</segment>
<segment id="25" parent="1027" relname="span">The lead member BCL-2 and its homologue BCL-XL</segment>
<segment id="26" parent="25" relname="elaboration">( BCL2L1 )</segment>
<segment id="27" parent="1026" relname="same_unit">are featured by the presence of four conserved BH domains ,</segment>
<segment id="28" parent="1026" relname="elaboration">three of which , BH1 , BH2 , and BH3 domains , are responsible for their antiapoptotic role mainly by interactions with other proapoptotic members of the BCL-2 family .</segment>
<segment id="29" parent="1030" relname="span">Inhibiting the activities of anti-apoptotic BCL-2 members by drugs or neutralizing by BH3 peptides</segment>
<segment id="30" parent="29" relname="purpose">to prime cancer cells to death</segment>
<segment id="31" parent="1029" relname="same_unit">has been regarded as effective therapeutic modalities .</segment>
<segment id="32" parent="1010" relname="joint">In another way , transcriptionally or post-transcriptionally repressing the expression levels of anti-apoptotic BCL-2 members in cancer is also promising .</segment>
<segment id="33" parent="1010" relname="joint">However , the mechanism regulating the expression of BCL-2 family members still remain unclear .</segment>
<segment id="34" parent="1034" relname="span">Autophagy is an evolutionarily-conserved catabolic process ,</segment>
<segment id="35" parent="1035" relname="joint">during which “ useless ” proteins and damaged organelles are sequestrated into autophagosomes</segment>
<segment id="36" parent="1036" relname="span">and fused with lysosomes</segment>
<segment id="37" parent="36" relname="purpose">to form autolysosomes for bulk degradation of embedded components .</segment>
<segment id="38" parent="1039" relname="span">Except the dysregulated autophagic process</segment>
<segment id="39" parent="38" relname="elaboration">defined as type II programmed cell death ,</segment>
<segment id="40" parent="1038" relname="same_unit">autophagy is generally regarded as protective cellular process .</segment>
<segment id="41" parent="1042" relname="same_unit">The recycled peptides , nucleotides and lipids together with the energy</segment>
<segment id="42" parent="1042" relname="same_unit">are critical to the maintenance of cellular homeostasis</segment>
<segment id="43" parent="1043" relname="span">and support tumor cells</segment>
<segment id="44" parent="43" relname="purpose">to survive under stressful environment .</segment>
<segment id="45" parent="1046" relname="span">Autophagy-related genes</segment>
<segment id="46" parent="45" relname="elaboration">( ATGs ) ,</segment>
<segment id="47" parent="1048" relname="span">including ULK1</segment>
<segment id="48" parent="47" relname="restatement">( ATG1 ) , ATG3 , and ATG12 etc. , are involved in the distinct stages of autophagy :</segment>
<segment id="49" parent="1047" relname="same_unit">initiation , autophagosome nucleation , autophagosome membrane expansion , fusion with lysosome and the intravesicular components degradation .</segment>
<segment id="50" parent="1050" relname="span">Signaling pathways or critical factors are involved in regulating ATG genes ,</segment>
<segment id="51" parent="50" relname="elaboration">including Class III PI3-kinase complex I , mTORC I complex , mTORC II complex and Beclin1 et al. .</segment>
<segment id="52" parent="1051" relname="joint">However , the transcriptional regulation of the ATG genes is not fully explored .</segment>
<segment id="53" parent="1055" relname="span">In our previous study , Homeobox A9</segment>
<segment id="54" parent="53" relname="elaboration">( HOXA9 )</segment>
<segment id="55" parent="1054" relname="same_unit">was significantly downregulated</segment>
<segment id="56" parent="1051" relname="joint">and identified as tumor suppressor in cSCC tumors and cells .</segment>
<segment id="57" parent="1057" relname="span">HOXA9 functions in repressing the proliferation , migration and invasiveness ,</segment>
<segment id="58" parent="57" relname="circumstance">while promoting apoptosis of cSCC cells .</segment>
<segment id="59" parent="1051" relname="joint">However , the mechanisms about how HOXA9 regulate apoptosis has not been explored</segment>
<segment id="60" parent="1051" relname="joint">and remain to be elucidated .</segment>
<segment id="61" parent="1062" relname="attribution">In this study , we found</segment>
<segment id="62" parent="1063" relname="span">RELA</segment>
<segment id="63" parent="62" relname="elaboration">( p65 subunit of NF-κB )</segment>
<segment id="64" parent="1062" relname="same_unit">is transcriptionally repressed by HOXA9 .</segment>
<segment id="65" parent="1065" relname="span">In cSCC , RELA transactivates BCL-XL</segment>
<segment id="66" parent="1067" relname="span">to antagonize apoptosis and ATG genes</segment>
<segment id="67" parent="66" relname="elaboration">( ULK1 , ATG3 , and ATG12 )</segment>
<segment id="68" parent="1067" relname="purpose">to promote autophagy .</segment>
<segment id="69" parent="1069" relname="span">Our study highlights a HOXA9-NF-κB axis regulates both the apoptosis and autophagy</segment>
<segment id="70" parent="69" relname="purpose">to promote tumor development in cSCC ,</segment>
<segment id="71" parent="1069" relname="elaboration">which may suggest novel intervention targets for cSCC therapy .</segment>
<group id="1000" type="span" />
<group id="1001" type="multinuc" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1001" relname="joint"/>
<group id="1003" type="multinuc" parent="1002" relname="same_unit"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1001" relname="joint"/>
<group id="1006" type="multinuc" parent="1005" relname="contrast"/>
<group id="1007" type="span" parent="1006" relname="same_unit"/>
<group id="1008" type="span" parent="1006" relname="same_unit"/>
<group id="1009" type="span" parent="1005" relname="contrast"/>
<group id="1010" type="multinuc" parent="1009" relname="span"/>
<group id="1011" type="span" parent="1010" relname="joint"/>
<group id="1012" type="multinuc" parent="11" relname="elaboration"/>
<group id="1013" type="span" parent="1012" relname="joint"/>
<group id="1015" type="span" parent="1010" relname="joint"/>
<group id="1016" type="span" parent="1015" relname="span"/>
<group id="1018" type="span" parent="1010" relname="joint"/>
<group id="1019" type="multinuc" parent="1018" relname="span"/>
<group id="1020" type="span" parent="1019" relname="joint"/>
<group id="1023" type="span" parent="1010" relname="joint"/>
<group id="1025" type="span" parent="1010" relname="joint"/>
<group id="1026" type="multinuc" parent="1025" relname="span"/>
<group id="1027" type="span" parent="1026" relname="same_unit"/>
<group id="1029" type="multinuc" parent="1010" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="same_unit"/>
<group id="1034" type="span" parent="1010" relname="joint"/>
<group id="1035" type="multinuc" parent="34" relname="elaboration"/>
<group id="1036" type="span" parent="1035" relname="joint"/>
<group id="1038" type="multinuc" parent="1010" relname="joint"/>
<group id="1039" type="span" parent="1038" relname="same_unit"/>
<group id="1042" type="multinuc" parent="1010" relname="joint"/>
<group id="1043" type="span" parent="1010" relname="joint"/>
<group id="1045" type="span" parent="1010" relname="joint"/>
<group id="1046" type="span" parent="1045" relname="span"/>
<group id="1047" type="multinuc" parent="1046" relname="elaboration"/>
<group id="1048" type="span" parent="1047" relname="same_unit"/>
<group id="1049" type="multinuc" parent="1010" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="contrast"/>
<group id="1051" type="multinuc" parent="1049" relname="contrast"/>
<group id="1054" type="multinuc" parent="1051" relname="joint"/>
<group id="1055" type="span" parent="1054" relname="same_unit"/>
<group id="1057" type="span" parent="1051" relname="joint"/>
<group id="1061" type="span" parent="1051" relname="joint"/>
<group id="1062" type="multinuc" parent="1061" relname="span"/>
<group id="1063" type="span" parent="1062" relname="same_unit"/>
<group id="1065" type="span" parent="1051" relname="joint"/>
<group id="1066" type="span" parent="65" relname="purpose"/>
<group id="1067" type="span" parent="1066" relname="span"/>
<group id="1068" type="span" parent="1051" relname="joint"/>
<group id="1069" type="span" parent="1068" relname="span"/>
	</body>
</rst>
